VAL-083 (Dianhydrogalactitol): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

30 March 2024

  • curprev 20:3920:39, 30 March 2024‎ Lazy talk contribs‎ 1,923 bytes +1,923‎ Created page with "{{TreatmentInfo |drug_name=VAL-083 (Dianhydrogalactitol) |FDA_approval=Approved in China for CML and lung cancer; not yet approved outside of China for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) with unmethylated MGMT promoter |clinical_trial_phase=Phase 2 (ongoing evaluation in GBM AGILE for various GBM subtypes) |common_side_effects=Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083 |..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=VAL-083_(Dianhydrogalactitol)"